Key Highlights:
- Nearly €8 million invested in Archet 2’s infrastructure, aiming to improve healthcare services and the well-being of patients and staff.
- Specific modernization of the pediatric department with €3.41 million for family-optimized individual rooms.
- Allocation of €4.46 million to the medical genetics department for its modernization and relocation, consolidating its status as a reference center for rare diseases.
The Nice University Hospital, with Archet 2 as its flagship, inaugurates a new era in the field of health on the Côte d’Azur, thanks to a substantial investment of nearly €8 million. This initiative reflects an ambitious strategy to reinvent the standards of hospital care and medical treatment.
Renovation Focused on Patients and Research
The €3.41 million envelope dedicated to the pediatric department marks a shift towards a more humane and reassuring hospitalization for children and their families. The transformation has made it possible to set up individual rooms with all the necessary amenities, promoting a secure environment for young patients.
The pediatric oncohematology department is thus equipped with a renovated space capable of effectively meeting the complex needs of treatments and follow-up of serious illnesses in children.
Medical Genetics Department, a Pillar of Innovation
The €4.46 million investment allocated to the medical genetics department reflects a desire to position Archet 2 as a leader in the treatment and research of rare diseases. This department strengthens its ability to offer cutting-edge care and to collaborate with national and international networks specialized in rare genetic diseases.
These renovations embody a vision of the future where the quality of care and patient comfort are priorities. The investment that Archet 2 is benefiting from is not just a financial commitment; it symbolizes an approach resolutely focused on medical excellence and respect for the human being in the care pathway.
Health Nice Côte d’Azur
- The Nice-based biotech Roca Therapeutics reaches a new milestone in its development
- Team Nice Côte d’Azur on a mission at the International Congress of Nutrition 2025
- Horus Pharma accelerates its international expansion across 8 new countries
- Health Afterwork in Nice: connecting innovators in the HealthTech sector
- Caranx Medical receives FDA clearance for its AI software guiding heart valve implantation
- Klava Innovation and Isis Medical: a partnership serving respiratory health
- Nice awarded the “Ma Ville se Ligue” label for its health prevention policy
- Investment: Sedna Santé lays the foundation stone for a new clinic in Nice
- Paul Martingell new Chief Executive Officer of the Virbac Group
- Team Nice Côte d’Azur at Bio International Convention 2025 : Smart Pipelines and Global Partnerships
